Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look. Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • BACKGROUND: Biologics have changed the way we treat moderate to severe psoriasis. Clinical trials for these patients offer the chance for those suffering from psoriasis to volunteer their time for the advancement of science while possibly gaining benefit from the efficacy of these medications.
    OBJECTIVE: All clinical trials have an ending by study design. In the past, trials ended abruptly but it is more common now for transitioning to the approved or another biologic to be offered. Sometimes, study subjects leave clinical trials suddenly for reasons of lack of efficacy, safety, withdrawing consent, being lost to follow-up, or personal reasons. Presenting early experience in transitioning is important for clinicians.
    METHODS: A retrospective case series of 11 patients who were exposed to brodalumab from clinical trials that ended abruptly and transitioned to secukinumab is presented.
    RESULTS: This is an early descriptive experience of transitioning between two IL-17 antagonists.
    LIMITATIONS: A small number of patients were available and a short follow up limited the data presented.
    CONCLUSION: Transitioning between two IL-17 antagonists is an option for those patients requiring such a change.

    J Drugs Dermatol. 2016;15(8):941-943.

publication date

  • August 1, 2016